Stocks
MoonLake’s Sonelokimab Faces Regulatory, Commercial Tests, RBC Says
MoonLake Immunotherapeutics' investigational drug, sonelokimab, is reportedly facing significant regulatory and commercial scrutiny, according to analysis by RBC.
MoonLake Immunotherapeutics' investigational drug, sonelokimab, is reportedly facing significant regulatory and commercial scrutiny, according to analysis by RBC.